No connection

Search Results

GNLN vs RKDA

GNLN
Greenlane Holdings, Inc.
BEARISH
Price
$2.88
Market Cap
$1.8M
Sector
Consumer Defensive
AI Confidence
95%
RKDA
Arcadia Biosciences, Inc.
BEARISH
Price
$1.18
Market Cap
$2.4M
Sector
Consumer Defensive
AI Confidence
95%

Valuation

P/E Ratio
GNLN
--
RKDA
--
Forward P/E
GNLN
-0.52
RKDA
-0.92
P/B Ratio
GNLN
0.36
RKDA
0.39
P/S Ratio
GNLN
0.42
RKDA
0.5
EV/EBITDA
GNLN
0.59
RKDA
0.41

Profitability

Gross Margin
GNLN
-286.22%
RKDA
36.04%
Operating Margin
GNLN
-2713.59%
RKDA
-152.61%
Profit Margin
GNLN
0.0%
RKDA
-48.15%
ROE
GNLN
-231.28%
RKDA
-45.14%
ROA
GNLN
-62.89%
RKDA
-32.71%

Growth

Revenue Growth
GNLN
-18.0%
RKDA
-25.9%
Earnings Growth
GNLN
--
RKDA
--

Financial Health

Debt/Equity
GNLN
0.0
RKDA
--
Current Ratio
GNLN
5.01
RKDA
3.09
Quick Ratio
GNLN
4.74
RKDA
2.42

Dividends

Dividend Yield
GNLN
--
RKDA
--
Payout Ratio
GNLN
0.0%
RKDA
0.0%

AI Verdict

GNLN BEARISH

GNLN exhibits extreme financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a total collapse in share price (-99.8% over 1 year). The company suffers from catastrophic operational inefficiency, evidenced by a negative gross margin of -286.22%, meaning it loses significant capital on every unit sold. Despite a high current ratio and zero debt, the business model is fundamentally broken with consistent quarterly losses over 17 consecutive periods and shrinking revenue. The stock is currently a value trap trading at a deep discount to book value but lacking any viable path to profitability.

Strengths
Zero reported debt/equity ratio
High current ratio (5.01) suggesting short-term liquidity
Low Price-to-Book ratio (0.36)
Risks
Negative gross margins (-286.22%) indicate a non-viable product pricing strategy
Severe revenue contraction (-18% YoY)
Consistent net losses across 17 consecutive quarters
RKDA BEARISH

RKDA exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all health metrics. Despite a strong current ratio of 3.09 suggesting short-term liquidity, the company suffers from severe operational inefficiency with an operating margin of -152.61% and declining year-over-year revenue growth of -25.90%. The catastrophic 5-year price decline of -98.8% and a 0/100 technical trend score confirm a persistent bearish trajectory. The stock is currently a classic value trap, trading at a low Price/Book (0.39) but lacking any catalyst for recovery.

Strengths
Strong short-term liquidity (Current Ratio: 3.09)
Positive Gross Margin (36.04%) indicating product viability
Low Price-to-Book ratio (0.39) suggesting deep discount to assets
Risks
Critical fundamental health (Piotroski F-Score: 0/9)
Severe operational losses (Operating Margin: -152.61%)
Negative revenue growth (-25.90% YoY)

Compare Another Pair

GNLN vs RKDA: Head-to-Head Comparison

This page compares Greenlane Holdings, Inc. (GNLN) and Arcadia Biosciences, Inc. (RKDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile